Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 4
2005 2
2006 1
2007 4
2008 3
2009 1
2010 3
2011 1
2012 3
2013 2
2014 2
2016 3
2017 7
2018 10
2019 7
2020 12
2021 10
2022 7
2023 11
2024 8
2025 9
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Tolaney SM, et al. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29. N Engl J Med. 2026. PMID: 41160818 Clinical Trial.
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramírez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr; DESTINY-Breast05 Trial Investigators. Loibl S, et al. N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661. Epub 2025 Dec 10. N Engl J Med. 2026. PMID: 41370739
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Barlesi F, Yao W, Duruisseaux M, Doucet L, Martínez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Barlesi F, et al. Among authors: gregorc v. Lancet. 2025 Aug 9;406(10503):615-626. doi: 10.1016/S0140-6736(25)00866-9. Lancet. 2025. PMID: 40783289 Clinical Trial.
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: gregorc v. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
Immunotherapeutic Advances for NSCLC.
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Massafra M, et al. Among authors: gregorc v. Biologics. 2021 Oct 8;15:399-417. doi: 10.2147/BTT.S295406. eCollection 2021. Biologics. 2021. PMID: 34675481 Free PMC article. Review.
CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches.
Tang J, Zheng Q, Wang Q, Zhao Y, Ananthanarayanan P, Reina C, Šabanović B, Jiang K, Yang MH, Meny CC, Wang H, Agerbaek MØ, Clausen TM, Gustavsson T, Wen C, Borghi F, Mellano A, Fenocchio E, Gregorc V, Sapino A, Theander TG, Fu D, Aicher A, Salanti A, Shen B, Heeschen C. Tang J, et al. Among authors: gregorc v. Cell Rep Med. 2024 Sep 17;5(9):101692. doi: 10.1016/j.xcrm.2024.101692. Epub 2024 Aug 19. Cell Rep Med. 2024. PMID: 39163864 Free PMC article.
113 results